Definitive Healthcare (DH)
(Delayed Data from NSDQ)
$5.62 USD
-0.03 (-0.53%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.61 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DH 5.62 -0.03(-0.53%)
Will DH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DH
DH or PRVA: Which Is the Better Value Stock Right Now?
Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now
DH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Medical Info Systems Stocks to Buy for Stable Returns
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for DH
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Definitive Healthcare launches redesigned mobile app to enhance access to healthcare commercial intelligence
Definitive Healthcare Corp. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare: Weak Near-Term Growth To Put Valuation In Rangebound
Small-cap, buy-rated stocks with positive estimate revision factors - BofA